Selected research
Market Structure
Global Pertuzumab Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Pertuzumab market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Pertuzumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Pertuzumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Pertuzumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Pertuzumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Pertuzumab include Abnova Corporation, Biocon Limited, Bio-Techne, Celltrion, InvivoGen, Pfizer and Novartis AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Pertuzumab market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Pertuzumab and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Pertuzumab sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pertuzumab market size, projected growth trends, production technologies, key applications, and end-use industries.
Pertuzumab Segment by Company
Abnova Corporation
Biocon Limited
Bio-Techne
Celltrion
InvivoGen
Pfizer
Novartis AG
Pertuzumab Segment by Type
Human Source
Animal Source
Pertuzumab Segment by Application
Hospital
Medical Center
Pertuzumab Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pertuzumab market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pertuzumab and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pertuzumab.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Pertuzumab market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pertuzumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Pertuzumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Pertuzumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Human Source
- Animal Source
Applications
- Hospital
- Medical Center
Companies covered
- Abnova Corporation
- Biocon Limited
- Bio-Techne
- Celltrion
- InvivoGen
- Pfizer
- Novartis AG
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Pertuzumab Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Pertuzumab Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Pertuzumab Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Pertuzumab Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Pertuzumab Market Dynamics
- 2.1 Pertuzumab Industry Trends
- 2.2 Pertuzumab Industry Drivers
- 2.3 Pertuzumab Industry Opportunities and Challenges
- 2.4 Pertuzumab Industry Restraints
3 Pertuzumab Market by Manufacturers
- 3.1 Global Pertuzumab Revenue by Manufacturers (2021-2026)
- 3.2 Global Pertuzumab Sales by Manufacturers (2021-2026)
- 3.3 Global Pertuzumab Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Pertuzumab Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Pertuzumab Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Pertuzumab Manufacturers, Product Type & Application
- 3.7 Global Pertuzumab Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Pertuzumab Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Pertuzumab Players Market Share by Revenue in 2025
- 3.8.3 2025 Pertuzumab Tier 1, Tier 2, and Tier 3
4 Pertuzumab Market by Type
- 4.1 Pertuzumab Type Introduction
- 4.1.1 Human Source
- 4.1.2 Animal Source
- 4.2 Global Pertuzumab Sales by Type
- 4.2.1 Global Pertuzumab Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Pertuzumab Sales by Type (2021-2032)
- 4.2.3 Global Pertuzumab Sales Market Share by Type (2021-2032)
- 4.3 Global Pertuzumab Revenue by Type
- 4.3.1 Global Pertuzumab Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Pertuzumab Revenue by Type (2021-2032)
- 4.3.3 Global Pertuzumab Revenue Market Share by Type (2021-2032)
5 Pertuzumab Market by Application
- 5.1 Pertuzumab Application Introduction
- 5.1.1 Hospital
- 5.1.2 Medical Center
- 5.2 Global Pertuzumab Sales by Application
- 5.2.1 Global Pertuzumab Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Pertuzumab Sales by Application (2021-2032)
- 5.2.3 Global Pertuzumab Sales Market Share by Application (2021-2032)
- 5.3 Global Pertuzumab Revenue by Application
- 5.3.1 Global Pertuzumab Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Pertuzumab Revenue by Application (2021-2032)
- 5.3.3 Global Pertuzumab Revenue Market Share by Application (2021-2032)
6 Global Pertuzumab Sales by Region
- 6.1 Global Pertuzumab Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Pertuzumab Sales by Region (2021-2032)
- 6.2.1 Global Pertuzumab Sales by Region (2021-2026)
- 6.2.2 Global Pertuzumab Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Pertuzumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Pertuzumab Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Pertuzumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Pertuzumab Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Pertuzumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Pertuzumab Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Pertuzumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Pertuzumab Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Pertuzumab Revenue by Region
- 7.1 Global Pertuzumab Revenue by Region
- 7.1.1 Global Pertuzumab Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Pertuzumab Revenue by Region (2021-2026)
- 7.1.3 Global Pertuzumab Revenue by Region (2027-2032)
- 7.1.4 Global Pertuzumab Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Pertuzumab Revenue (2021-2032)
- 7.2.2 North America Pertuzumab Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Pertuzumab Revenue (2021-2032)
- 7.3.2 Europe Pertuzumab Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Pertuzumab Revenue (2021-2032)
- 7.4.2 Asia-Pacific Pertuzumab Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Pertuzumab Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Pertuzumab Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Abnova Corporation
- 8.1.1 Abnova Corporation Company Information
- 8.1.2 Abnova Corporation Business Overview
- 8.1.3 Abnova Corporation Pertuzumab Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Abnova Corporation Pertuzumab Product Portfolio
- 8.1.5 Abnova Corporation Recent Developments
- 8.2 Biocon Limited
- 8.2.1 Biocon Limited Company Information
- 8.2.2 Biocon Limited Business Overview
- 8.2.3 Biocon Limited Pertuzumab Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Biocon Limited Pertuzumab Product Portfolio
- 8.2.5 Biocon Limited Recent Developments
- 8.3 Bio-Techne
- 8.3.1 Bio-Techne Company Information
- 8.3.2 Bio-Techne Business Overview
- 8.3.3 Bio-Techne Pertuzumab Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Bio-Techne Pertuzumab Product Portfolio
- 8.3.5 Bio-Techne Recent Developments
- 8.4 Celltrion
- 8.4.1 Celltrion Company Information
- 8.4.2 Celltrion Business Overview
- 8.4.3 Celltrion Pertuzumab Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Celltrion Pertuzumab Product Portfolio
- 8.4.5 Celltrion Recent Developments
- 8.5 InvivoGen
- 8.5.1 InvivoGen Company Information
- 8.5.2 InvivoGen Business Overview
- 8.5.3 InvivoGen Pertuzumab Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 InvivoGen Pertuzumab Product Portfolio
- 8.5.5 InvivoGen Recent Developments
- 8.6 Pfizer
- 8.6.1 Pfizer Company Information
- 8.6.2 Pfizer Business Overview
- 8.6.3 Pfizer Pertuzumab Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Pfizer Pertuzumab Product Portfolio
- 8.6.5 Pfizer Recent Developments
- 8.7 Novartis AG
- 8.7.1 Novartis AG Company Information
- 8.7.2 Novartis AG Business Overview
- 8.7.3 Novartis AG Pertuzumab Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Novartis AG Pertuzumab Product Portfolio
- 8.7.5 Novartis AG Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Pertuzumab Value Chain Analysis
- 9.1.1 Pertuzumab Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Pertuzumab Production Mode & Process
- 9.2 Pertuzumab Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Pertuzumab Distributors
- 9.2.3 Pertuzumab Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst